Dr. Wang on CAR T-Cell Therapy Resistance in MCL

Michael Wang, MD
Published: Friday, Sep 20, 2019



Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses CAR T-cell therapy and triple-resistance in mantle cell lymphoma (MCL).
 
No single treatment can cure every patient, says Wang. Having treatment options in non-Hodgkin lymphoma is necessary, but resistance to these treatments continues to pose a challenge.
 
Therapies such as rituximab (Rituxan), ibrutinib (Imbruvica) and venetoclax (Venclexta) saw some success in this space, but long-term remission responses were not durable and patients eventually developed resistance to both modalities, Wang says. 
 
The introduction of CAR T-cell therapy as a third treatment saw long-term remission in about 30% to 40% of patients, but a majority developed triple-resistance to chemotherapy, targeted therapy, and eventually, CAR T-cell therapy, he explains.
 
Personalized medicine may be the answer as it will expose driving resistance mechanisms in individual patients, Wang concludes.
SELECTED
LANGUAGE


Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses CAR T-cell therapy and triple-resistance in mantle cell lymphoma (MCL).
 
No single treatment can cure every patient, says Wang. Having treatment options in non-Hodgkin lymphoma is necessary, but resistance to these treatments continues to pose a challenge.
 
Therapies such as rituximab (Rituxan), ibrutinib (Imbruvica) and venetoclax (Venclexta) saw some success in this space, but long-term remission responses were not durable and patients eventually developed resistance to both modalities, Wang says. 
 
The introduction of CAR T-cell therapy as a third treatment saw long-term remission in about 30% to 40% of patients, but a majority developed triple-resistance to chemotherapy, targeted therapy, and eventually, CAR T-cell therapy, he explains.
 
Personalized medicine may be the answer as it will expose driving resistance mechanisms in individual patients, Wang concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x